Author： Zakeri Rosita Burnett John C.
Publisher： NRC Research Press
ISSN： 1205-7541
Source： Canadian Journal of Physiology and Pharmacology, Vol.89, Iss.8, 2011-08, pp. : 593-601
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create “designer” chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.
Related content
Access to resources
Recommend
Natriuretic Peptides: Future Use?
Heart Drug, Vol. 2, Iss. 1, 2002-04 ,pp. :
Autocrine and paracrine actions of natriuretic peptides in the heart
By D'Souza S.P. Davis M. Baxter G.F.
Pharmacology and Therapeutics, Vol. 101, Iss. 2, 2004-02 ,pp. :
Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology, Vol. 4, Iss. 2, 2009-05 ,pp. :